The product page went live on a Sunday. By Wednesday, it was gone.
For exactly three days in February 2026, Hims & Hers—the telehealth darling that had ridden the weight-loss drug boom to a multi-billion-dollar valuation—sold what it called a "compounded oral Wegovy pill" for $49 a month. The pitch was irresistible in its simplicity: the same blockbuster medication Hollywood swore by, now in a convenient tablet, at a fraction of the retail price. No insurance hassles. No pharmacy runs. Just click, pay, and wait for the package.
Then the regulators arrived. And the lawyers. And the short sellers.
The Food and Drug Administration issued what's known in regulatory circles as an "intent to act" statement—bureaucratic language that means, roughly, we're coming for you. The Department of Health and Human Services referred the matter to Justice. Novo Nordisk, the Danish pharmaceutical giant behind the actual Wegovy, filed suit. Hims pulled the product before the week was out. The stock collapsed more than 20%.
It was the most spectacular flameout in what has become a sweeping enforcement campaign against the telehealth industry's most lucrative side hustle: selling knockoff versions of Ozempic, Wegovy, and Mounjaro to Americans desperate to lose weight. But the Hims debacle was merely the exclamation point on a regulatory reckoning that had been building for over a year—one that's rewriting the economics of digital weight-loss care and forcing dozens of telehealth platforms to choose between shuttering their cash cows or selling branded drugs at more than double the price.
The compounded GLP-1 market, worth hundreds of millions in monthly revenue across the telehealth sector, didn't collapse overnight. But looking back, the sequence of enforcement actions from late 2024 through early 2026 reads less like a series of warnings and more like a systematic dismantling.
How the Loophole Worked (Until It Didn't)
Federal law permits compounding pharmacies—facilities that custom-mix medications for individual patients—to replicate FDA-approved drugs, but only under specific circumstances. The key constraint: the original drug must be in short supply.
For roughly two years, that loophole was wide enough to drive a telehealth empire through. Novo's Wegovy and Eli Lilly's Mounjaro were perpetually back-ordered. Demand was insatiable. Supply chains buckled. And in that gap, an entire industry sprouted.
Platforms like Hims, Noom, and a constellation of smaller operators built business lines around $180-to-$200-per-month "personalized" semaglutide or tirzepatide injections, sourced from compounding partners operating under what the industry preferred to call discretionary enforcement. Patients got their drugs. Telehealth companies booked the revenue. Compounders filled the orders.
Everyone, it seemed, was making money. Except the pharmaceutical companies watching their patents get sidestepped and the FDA, which was getting an earful from those same pharmaceutical companies.
The regulatory vise began tightening in December 2024. That's when the FDA declared the tirzepatide shortage resolved and set enforcement-discretion wind-down deadlines: February 18, 2025, for smaller 503A compounders, and March 19 for larger 503B facilities. Two months later—February 21, 2025—the agency did the same for semaglutide. Discretion for 503A compounding would end April 22; 503B operations had until May 22.
Those weren't suggestions. They were countdown clocks.
When a compounding trade group challenged the FDA's shortage determinations in court, seeking a preliminary injunction to keep the party going a little longer, the court denied it. That was late April 2025. The legal path to enforcement was now clear.
Fifty Warning Letters in a Single Month
Then came September. The FDA sent what industry insiders started calling "the wave"—more than 50 warning letters, according to trade publication tallies, targeting telehealth platforms and compounders for "false or misleading" promotion of compounded GLP-1s.
The violations the agency cited weren't minor technical infractions. They were misbranding charges under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act—the kind of language that gets compliance officers' attention. The FDA took particular issue with marketing claims that suggested compounded products were equivalent to brand-name drugs, or that they contained the "same active ingredient," or worse, that they were essentially "generic" versions.
One September 9 letter illustrates the pattern. Statements implying FDA approval or therapeutic equivalence triggered the misbranding hammer. Companies that had been dancing in the regulatory gray zone suddenly found themselves under harsh fluorescent lights.
The FDA also started publishing data. On its safety information page for GLP-1 medications—updated through July 31, 2025—the agency cataloged 605 adverse event reports associated with compounded semaglutide and 545 linked to compounded tirzepatide. Dosing errors, improperly refrigerated shipments, fraudulent labeling. The list was long enough to make the agency's point: this wasn't just about protecting Big Pharma's revenue. Patient safety was genuinely at risk.
The FDA also dropped a clarification that blindsided some operators: salt forms of semaglutide—sodium or acetate variants marketed by certain compounders—constituted different active ingredients and therefore weren't eligible for compounding under the shortage exemption. It was a technical ruling with profound business implications.
February 2026: The Hammer Falls
If September's warning letters were meant to get the industry's attention, the February 6, 2026, announcement was designed to end the conversation entirely.
The FDA stated its intent to take action against non-FDA-approved GLP-1 drugs and misleading direct-to-consumer marketing, explicitly naming both compounding pharmacies and telehealth marketers. More ominously, HHS simultaneously referred cases to the Department of Justice for potential criminal or civil enforcement. Not regulatory slaps on the wrist. Potential prosecution.
Hims became the cautionary tale everyone would cite for the next six months.
The company had launched compounded semaglutide injections back in May 2024. CEO Andrew Dudum publicly touted a year's worth of supply-chain work and pricing under $200 per month—positioning Hims as the democratizer of weight-loss drugs, the company that would bring Ozempic to the masses. Wall Street loved the narrative. For a while.
By February 2025, when the FDA declared the semaglutide shortage over, Hims stock dropped 26% in a single trading session. The company had already acquired a peptide manufacturing facility and an at-home diagnostics lab called Trybe Labs—investments that looked prescient when compounding was thriving and precarious now that the regulatory winds had shifted.
But Hims didn't retreat. In July 2025, it released internal data claiming an average 10.3% weight loss at six months among patients using its compounded GLP-1 products, with 75% persistence at six months and low self-reported adverse events. Dudum doubled down in earnings calls, framing the business as a long-term bet on personalized care.
Behind the scenes, the pressure was mounting. In June 2025, Novo Nordisk terminated what had been a tentative collaboration with Hims, over what trade publications described as "illegal mass compounding" concerns. It was a public rebuke, the kind that signals a company is being pushed out of the club.
The oral semaglutide launch in February 2026 was, in retrospect, either a desperate gambit or a profound miscalculation. Maybe both. The product was live for three days. Then the FDA announcement hit. Then the Novo lawsuit. Then the stock cratered.
The era of compounded GLP-1s as a viable telehealth business model was effectively over.
The Ones Who Saw It Coming
Not every platform faced the same fate, though. Some made different bets.
Ro, a direct Hims competitor, pivoted in April 2025 by integrating with Novo Nordisk's NovoCare Pharmacy program. NovoCare had launched a month earlier with a straightforward value proposition: $499 per month cash price for all Wegovy doses, with home delivery handled by CenterWell pharmacy. No insurance necessary. No prior authorization gauntlet. Just a flat price—steep compared to compounded alternatives, yes, but dramatically lower than Wegovy's $1,300-plus list price.
Novo later extended that pricing to retail pharmacies and forged partnerships with select telehealth platforms. Ro was in. So was LifeMD. For a brief moment, even Hims was on the list—until the relationship soured.
Ro's CEO framed the NovoCare integration as offering "the lowest cash price" while expanding access through Ro's existing telehealth infrastructure. The subtext was clear: we're getting out of the regulatory crossfire and into a legitimate distribution partnership.
In December 2025, Ro published peer-reviewed data in the journal Obesity showing 16.6% mean weight loss at roughly 68 weeks among 655 patients receiving branded semaglutide via its telehealth service. The adverse event profile was consistent with clinical trials. It was the kind of real-world evidence that could help with payer negotiations down the line—and it positioned Ro as a serious clinical player, not just a drug reseller riding regulatory ambiguity.
By January 2026, Ro had added Novo's newly approved oral Wegovy pill to its platform via the NovoCare integration. LifeMD followed a similar trajectory, announcing bundled pricing in April 2025: $299 for the first month including care, $599 thereafter for self-pay patients. In January 2026, LifeMD expanded its Novo collaboration to include oral Wegovy.
These partnerships represent a fundamental business model shift, and not necessarily a more profitable one in the near term. Where compounded semaglutide might have generated $180 to $200 per month in revenue at minimal regulatory risk during the shortage window, branded Wegovy at $499 carries tighter margins—after Novo's cut, after fulfillment costs—but eliminates the compliance and litigation exposure. For platforms willing to make that trade, the path forward is clearer. Whether it's sustainable depends on volume, retention, and the ability to layer in ancillary services that justify the care fee beyond just dispensing pills.
Pharma Plays Offense
Novo Nordisk and Eli Lilly weren't content to let the FDA do all the heavy lifting. Both companies pursued aggressive legal strategies alongside capacity expansions designed to eliminate the supply shortages that had created the compounding loophole in the first place.
Novo filed multiple lawsuits starting in 2023, alleging impure or misbranded "semaglutide" products from various compounders. In April 2025, the company secured a significant legal win that effectively barred many compounded Wegovy and Ozempic copies. The February 2026 lawsuit against Hims over oral semaglutide was simply the latest—and highest-profile—salvo.
Eli Lilly took a parallel approach with tirzepatide. Beginning in 2023, the company went after med spas and compounders. Then in April 2025, Lilly targeted telehealth operators directly: Mochi Health, Fella Health, Willow Health, and Henry Meds all found themselves in the legal crosshairs, accused of deceptive marketing and mass-marketed "personalized" tirzepatide that violated federal compounding rules.
At the same time—and perhaps more importantly—both manufacturers ramped manufacturing capacity at a breakneck pace. Novo invested over $4 billion in North Carolina fill-finish expansions and acquired Catalent fill-finish sites to broaden Wegovy and Ozempic supply, with production ramps extending through 2029. Lilly announced more than $9 billion in Indiana API site expansions for tirzepatide, alongside multiple U.S. and European plants to scale Mounjaro and Zepbound production.
The strategy was elegant in its simplicity: eliminate the shortage, eliminate the loophole, then offer a cash-pay option that undercuts compounders while preserving premium pricing for insured patients.
NovoCare is the strategic capstone. By offering $499-per-month cash pricing through select telehealth partners—steep compared to what compounders charged, but accessible compared to the sticker-shock list price—Novo captured patients transitioning away from shuttered compounding channels. Former competitors became distribution partners, with standardized pricing and fulfillment handled through CenterWell.
It's a masterclass in turning a regulatory threat into a controlled distribution strategy.
The Market That's Too Big to Ignore
This entire regulatory saga is playing out against a backdrop of explosive, almost surreal demand.
By May 2025, GLP-1 drugs represented 52% of all U.S. diabetes prescription volume, up from 18% in 2020, according to IQVIA data. Monthly prescription volume surged from 680,000 in January 2020 to 4.7 million in May 2025. Those aren't incremental growth figures. That's a paradigm shift in how Americans manage weight and metabolic disease.
Employer coverage for GLP-1s "primarily for weight loss" has grown, but remains frustratingly uneven for patients. A 2025 KFF survey found 16% coverage among firms with 200 to 999 workers, 30% among those with 1,000 to 4,999 employees, and 43% at firms with 5,000 or more workers. Larger employers are more willing to cover the drugs, but even among those that do, utilization management is near-universal. Eighty-five percent use prior authorization or step therapy, according to a 2024 International Foundation of Employee Benefit Plans survey. Translation: getting coverage is one thing; actually accessing the drugs can be another bureaucratic ordeal entirely.
A Willis Towers Watson analysis in April 2025 estimated GLP-1s can represent 3% to 4% of total medical and pharmacy spend for employers—a cost burden significant enough to make benefits managers nervous.
Medicare and Medicaid coverage remains even more limited. The Centers for Medicare & Medicaid Services allows Part D plans to cover Wegovy only for patients with the cardiovascular risk-reduction indication Novo secured in March 2024—not for weight loss alone. A proposed broader anti-obesity coverage reinterpretation was left unfinalized in the April 2025 CY2026 Medicare Advantage and Part D rule. In December 2025, CMS launched the BALANCE model, a voluntary pilot program to let state Medicaid agencies and Part D sponsors experiment with covering GLP-1s while controlling costs.
But meaningful expansion remains uncertain. Which is to say, the regulatory path for coverage is still being negotiated.
Market projections, meanwhile, have reached the kind of numbers that make analysts check their spreadsheets twice. Morgan Stanley forecasts the global obesity drug market could hit $150 billion by 2035, up from roughly $15 billion in 2024 sales. Goldman Sachs estimates $130 billion by 2030. With approximately 40% of U.S. adults living with obesity and severe obesity affecting nearly 10%, the addressable population is enormous—and largely untapped.
The question is who captures that value, and how.
What It Means for Founders (and Why Most Options Are Bad)
For telehealth platforms and digital health founders watching this unfold, the next 12 to 24 months will separate the survivors from the casualties. The strategic choices ahead are limited, and none of them are particularly attractive compared to the compounding gold rush that just ended.
Partner with brand manufacturers. The NovoCare model—and any similar programs Lilly might eventually launch—offers regulatory safety and standardized economics, but thinner margins than compounding once provided. Ro and LifeMD have made this bet. Success depends on volume, retention, and the ability to layer in ancillary services: behavioral support, lab monitoring, comorbidity management, the kind of wraparound care that justifies a subscription fee beyond just drug dispensing. If you can't add value beyond being a licensed prescriber with a website, the economics probably don't work.
Exit GLP-1s entirely. Smaller telehealth operators without the scale to negotiate manufacturer partnerships—or the compliance infrastructure to absorb ongoing regulatory scrutiny—may simply walk away. The risk-reward calculus has shifted. Continuing to offer compounded GLP-1 products post-shortage now carries material regulatory and litigation risk. And the economics of branded resale may not pencil out at modest volumes. For platforms that can't clear 10,000 or 20,000 patients, this might be the prudent choice, even if it means leaving revenue on the table.
Navigate the remaining compounding gray zones. Some operators are exploring what might charitably be called "personalized exception" narratives—arguing that specific patient populations require custom formulations. Dose titrations outside labeled ranges. Additive vitamins or nutrients. Alternate delivery mechanisms. Maybe there's a legitimate medical case. Maybe it's regulatory arbitrage 2.0.
State pharmacy boards are scrutinizing these claims closely. California adopted tighter "essentially a copy" rules in 2025, requiring documented, clinically significant differences before compounding is permissible. Washington and Oregon have issued statements reiterating that semaglutide salts are off-limits and that compliance failures risk disciplinary action, up to and including license suspension. Expect continued audits and enforcement actions at the state level, particularly in California, Washington, Oregon, and other jurisdictions with active, well-resourced pharmacy boards.
Translation: there might be narrow lanes where legitimate compounding still makes sense. But they're narrow. And getting narrower.
Invest in outcomes data. Ro's peer-reviewed publication in Obesity and its presentations at ObesityWeek 2025 represent a playbook worth studying. Generate real-world evidence that telehealth-delivered GLP-1 care produces outcomes comparable to clinical trials. That kind of data can influence payer coverage decisions, ease utilization management criteria, and position a platform as a clinical partner rather than just a distribution channel.
For platforms that bundle behavioral support, cardiovascular risk documentation, and comprehensive lab monitoring, there's a path to aligning with CMS-recognized indications—like Wegovy's cardiovascular benefit—which might unlock Medicare coverage under existing rules or expedite inclusion in BALANCE model pilots. It's a longer, harder road than just selling compounded drugs, but it's arguably the only sustainable one.
Prepare for next-generation products. The pipeline is robust, and it's moving fast. Lilly's oral GLP-1, orforglipron, is expected to gain FDA approval in 2026, with company executives signaling it will expand the market rather than cannibalize injectable sales. Novo's oral Wegovy pill received approval in December 2025. Amgen's MariTide—a monthly injectable with GLP-1/GIPR/GCGR activity—showed approximately 20% weight loss at 52 weeks in Phase 2 trials; Phase 3 studies are underway. Viking Therapeutics' VK2735, a dual GLP-1/GIP agonist, reported 14.7% weight loss at 13 weeks in subcutaneous Phase 2 and 12.2% in the oral formulation.
As these drugs advance—and as competition inevitably drives pricing down—telehealth platforms may find new partnership opportunities or face further fragmentation in an increasingly crowded competitive landscape. The early movers who establish manufacturer relationships now may have an advantage. Or maybe not. The market is shifting fast enough that six-month-old assumptions are already outdated.
One more thing worth noting: the Federal Trade Commission's enforcement action against NextMed, finalized in December 2025, sets a precedent that should make every telehealth marketer nervous. The FTC charged the telemedicine firm with misleading pricing, fake reviews, and deceptive GLP-1 weight-loss claims. The settlement imposed financial penalties and strict marketing and cancellation rules.
Telehealth operators promoting GLP-1s should assume heightened scrutiny of advertising practices, pricing transparency, patient testimonials, and subscription cancellation policies. The regulatory crosshairs aren't just on the drugs themselves. They're on how those drugs are sold.
What Comes After the Gold Rush
The compounding loophole is closed. That much is certain.
The FDA's February 2026 announcement, with its accompanying DOJ referrals, signals that further enforcement—more warning letters, potential injunctions, possibly even criminal or civil actions—will
